文献速递生殖医学

胚胎移植日血清孕酮水平对妊娠结局的影响:阴道孕酮人工周期前瞻性队列研究

Impact of low serum progesterone levels on the day of embryo transfer on pregnancy outcome: a prospective cohort study in artificial cycles with vaginal progesterone.
PubMed 文献 · Hum Reprod · 2021-01-01

该前瞻性队列研究纳入1205例接受雌二醇戊酸酯和微粒化阴道孕酮人工周期准备的患者,分析移植日血清孕酮水平与持续妊娠率的关系。结果显示血清孕酮<8.8 ng/ml组持续妊娠率(36.6% vs 54.4%)和活产率(35.5% vs 52.0%)显著降低,且为独立影响因素。建议监测黄体中期孕酮水平并调整剂量。

要点

  • 移植日血清孕酮<8.8 ng/ml显著降低持续妊娠率和活产率
  • 血清孕酮<8.8 ng/ml是持续妊娠率的独立影响因素
  • 使用阴道孕酮时建议监测黄体中期孕酮以调整剂量

核心结论

  • 移植日血清孕酮<8.8 ng/ml降低自身卵母细胞或供卵周期的持续妊娠率。

研究设计与样本

  • 前瞻性队列研究,2017年9月至2018年11月纳入1205例人工周期准备移植的患者,最终分析1150例。

主要发现

  • 血清孕酮<8.8 ng/ml(第30百分位)组持续妊娠率36.6% vs 54.4%,活产率35.5% vs 52.0%,均显著降低。
  • 多因素logistic回归显示血清孕酮<8.8 ng/ml是总体人群及三个治疗组中持续妊娠率的独立影响因素。
  • 血清孕酮与BMI、体重及末次孕酮给药至采血时间呈负相关,与年龄、身高及激素替代治疗天数呈正相关。
  • 多因素回归显示仅体重是血清孕酮<8.8 ng/ml的独立影响因素。
  • 持续妊娠患者中,无论血清孕酮高于或低于8.8 ng/ml,产科和围产期结局无差异。

关键数值与推荐

  • 血清孕酮阈值8.8 ng/ml(第30百分位)。
  • 阴道微粒化孕酮用法:400 mg,每日两次。
  • 纳入标准:年龄≤50岁,子宫内膜三线征且厚度≥6.5 mm,移植1或2个囊胚。

临床怎么用

  • 人工周期使用阴道孕酮时,建议在黄体中期监测血清孕酮水平。
  • 根据血清孕酮水平调整孕酮剂量,以优化妊娠结局。

局限性

  • 仅纳入使用阴道微粒化孕酮的患者,推广至其他孕酮给药形式需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is there a serum progesterone (P) threshold on the day of embryo transfer (ET) in artificial endometrium preparation cycles below which the chances of ongoing pregnancy are reduced? SUMMARY ANSWER: Serum P levels <8.8 ng/ml on the day of ET lower ongoing pregnancy rate (OPR) in both own or donated oocyte cycles. WHAT IS KNOWN ALREADY: We previously found that serum P levels <9.2 ng/ml on the day of ET significantly decrease OPR in a sample of 211 oocyte donation recipients. Here, we assessed whether these results are applicable to all infertile patients under an artificial endometrial preparation cycle, regardless of the oocyte origin. STUDY DESIGN, SIZE, DURATION: This prospective cohort study was performed between September 2017 and November 2018 and enrolled 1205 patients scheduled for ET after an artificial endometrial preparation cycle with estradiol valerate and micronized vaginal P (MVP, 400 mg twice daily). PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients ≤50 years old with a triple-layer endometrium ≥6.5 mm underwent transfer of one or two blastocysts. A total of 1150 patients treated with own oocytes without preimplantation genetic testing for aneuploidies (PGT-A) (n = 184), own oocytes with PGT-A (n = 308) or donated oocytes (n = 658) were analyzed. The primary endpoint was the OPR beyond pregnancy week 12 based on serum P levels measured immediately before ET. MAIN RESULTS AND THE ROLE OF CHANCE: Women with serum P levels <8.8 ng/ml (30th percentile) had a significantly lower OPR (36.6% vs 54.4%) and live birth rate (35.5% vs 52.0%) than the rest of the patients. Multivariate logistic regression showed that serum P < 8.8 ng/ml was an independent factor influencing OPR in the overall population and in the three treatment groups. A significant negative correlation was observed between serum P levels and BMI, weight and time between the last P dose and blood tests and a positive correlation was found with age, height and number of days on HRT. Multivariate logistic regression showed that only body weight was an independent factor for presenting serum P levels <8.8 ng/ml. Obstetrical and perinatal outcomes did not differ in patients with ongoing pregnancy regardless of serum P levels being above/below 8.8 ng/ml. LIMITATIONS, REASONS FOR CAUTION: Only women with MVP were included. Extrapolation to other P administration forms needs to be validated. WIDER IMPLICATIONS OF THE FINDINGS: This study identified the threshold of serum P as 8.8 ng/ml on the day of ET for artificial endometrial preparation cycles necessary to optimize outcomes, in cycles with own or donated oocytes. One-third of patients receiving MVP show inadequate levels of serum P that, in turn, impact the success of the ART cycle. Monitoring P levels in the mid-luteal phase is recommended when using MVP to adjust the doses according to the needs of the patient. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: NCT03272412.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Labarta E, Mariani G, Paolelli S, et al. Impact of low serum progesterone levels on the day of embryo transfer on pregnancy outcome: a prospective cohort study in artificial cycles with vaginal progesterone. Hum Reprod. 2021. PMID: 33340402. doi:10.1093/humrep/deaa322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。